TerSera Therapeutics
As of the edition of 20 October 2026, TerSera Therapeutics runs 4 drugs, 4 of them marketed; it is on route A at 0 targets and on route B at 4 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Total | 4 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Goserelin | none listed | 1 |
| Meloxicam | none listed | 1 |
| Telotristat ethyl | Ends 2031 (patent) | 4 |
| Rolapitant | Ends 2028 (patent) | 2 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 4 targets.
All 4 rows on route A or B
In the product4 company-target rows on route A or B; 1 is not shown here, and no score is.
See all 4 targets where TerSera Therapeutics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.